摘要
背景:重度抑郁症(MDD)及其对抗抑郁药物的频繁部分反应是一个主要的健康问题,因此也是一个重要的研究重点。尽管努力,MDD的发病机制和抗抑郁作用机制仅部分了解。在过去的几年里,人们提出需要重新考虑抑郁症和精神疾病的分类,以便提供一种更密切地反映与疾病发病机制相关的生物学背景及其在治疗中的作用/意义的疾病学。美国国家心理健康研究所(NIMH)提出的分类,即研究领域标准(RDoC),可能是指导这一方向研究的一个关键框架。 方法:在PubMed和谷歌学者数据库上进行文献检索,以检索有关抗抑郁药对特定RDoC结构的影响的数据。此外,通过药物库数据库确定了感兴趣的药物的靶标,并讨论了它们在RDoC构建中的可能功能。 讨论:在这篇综述中,我们总结并讨论了临床前和临床研究结果的意义,这些研究是对与抑郁表型和抗抑郁作用相关的特定RDoC范式的研究。 结论:RDoC框架可能有助于进一步使用抗抑郁药物和开发针对特定抑郁症状的新化合物。
关键词: 研究领域标准,重度抑郁症,抗抑郁药,行为范式,RDoC构建,药物靶点。
Current Medicinal Chemistry
Title:Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression
Volume: 28 Issue: 22
关键词: 研究领域标准,重度抑郁症,抗抑郁药,行为范式,RDoC构建,药物靶点。
摘要:
Background: Major Depressive Disorder(MDD) and its frequent partial response to antidepressants are a major health concern and therefore an important focus of research. Despite the efforts, MDD pathogenesis and the mechanisms of antidepressant action are only partially understood. In the last few years, the need of rethinking the classification of depressive disorders and psychiatric disorders, in general, has been suggested, in order to provide a nosology that reflects more closely the biological background associated with disease pathogenesis and its role/significance in treatment. The classification proposed by the National Institute of Mental Health (NIMH), namely the research domain criteria (RDoC), may represent a key framework to guide research in this direction.
Methods: A literature search was performed on PubMed and Google Scholar databases in order to retrieve data regarding Antidepressants effects on specific RDoC constructs. Further, the targets of drugs of interest were identified through the Drug bank database, and their possible function within RDoC constructs was discussed.
Discussion: In this review, we summarize and discuss the significance of the results of pre-clinical and clinical studies investigating specific RDoC paradigms relevant to depressive phenotypes and antidepressant effects.
Conclusion: The RDoC framework may facilitate a more specific use of antidepressants based on the individual’s spectrum of symptoms and the development of new compounds that target specific depressive symptoms.
Export Options
About this article
Cite this article as:
Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression, Current Medicinal Chemistry 2021; 28 (22) . https://dx.doi.org/10.2174/0929867328666210104104938
DOI https://dx.doi.org/10.2174/0929867328666210104104938 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis and Subtype of Intracerebral Hemorrhage (ICH) and ICH Score Determines Prognosis
Current Neurovascular Research Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets Malformations of the Female Genital Tract and Embryological Bases
Current Women`s Health Reviews Mitochondrial Encephalomyopathies in Children. Part I: Conventional MR Imaging Findings
Current Medical Imaging The Phosphodiesterase III Inhibitor Cilostazol Ameliorates Ethanolinduced Endothelial Dysfunction
Current Neurovascular Research Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Diagnostic Value of the Early Heart-to-Mediastinum Count Ratio in Cardiac 123I-mIBG Imaging for Parkinson's Disease
Current Radiopharmaceuticals 3-(1H-Pyrrol-2-yl)-2-oxazolidinones as Novel Monoamine Oxidase Type A Inhibitors
Medicinal Chemistry The Potential Roles of Metallothionein as a Therapeutic Target for Cerebral Ischemia and Retinal Diseases
Current Pharmaceutical Biotechnology Preface
Current Medicinal Chemistry Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Commentary: Olfactory Dysfunction in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Promoting Adult Hippocampal Neurogenesis: A Novel Strategy for Antidepressant Drug Screening
Current Medicinal Chemistry Interleukin-10
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Emerging Role of Antioxidants in the Protection of Uveitis Complications
Current Medicinal Chemistry Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Current Neuropharmacology Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease
Current Enzyme Inhibition A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Double Layered Hydroxides as Potential Anti-Cancer Drug Delivery Agents
Mini-Reviews in Medicinal Chemistry Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy
CNS & Neurological Disorders - Drug Targets